Refractory thrombotic thrombocytopenic purpura and membranoproliferative glomerulonephritis successfully treated with rituximab: A case associated with hepatitis C virus infection

Hong Kong Medical Journal

Volumn 15, Issue 3, 2009, Pages 201-208

  Mak, S K ^a   Lo, K Y ^a   Lo, M W ^b   Chan, S F ^a   Lo, K C ^a   Wong, Y Y ^a   Tong, Gensy M W ^a   Wong, P N ^a   Ma, Edmond S K ^c   Wong, Andrew K M ^a  

^a KWONG WAH HOSPITAL   (Hong Kong)

^b Our Lady of Maryknoll Hospital Hong Kong   (Hong Kong)

^c HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

Glomerulonephritis, membranous; Hepatitis C; Purpura, thrombocytopenic, idiopathic; Rituximab; Thrombocytopenia

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VIRUS RNA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; CREATININE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LIVER BIOPSY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PLASMAPHERESIS; RELAPSE; REMISSION; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTERY; BLOOD; COMORBIDITY; GENETICS; GLOMERULUS; HEPATITIS C VIRUS; LIVER; PATHOLOGY; TREATMENT FAILURE;

ADAM PROTEINS; ADULT; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; ARTERIES; COMORBIDITY; CREATININE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY GLOMERULUS; LIVER; PLASMAPHERESIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RNA, VIRAL; TREATMENT FAILURE;

EID: 67650503656     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003;14:1072-1081 (Pubitemid 36359290)
2. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-397
3. Bandarenko N, Brecher ME. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 1998;13:133-141
4. Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002;71:105-108
5. Zuber J, Martinez F, Droz D, Oksenhendler E, Legendre C; Groupe D'stude Des Nephrologues D'ile-de-France (GENIF). Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore) 2002;81:321-331 (Pubitemid 34755941)
6. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
7. Furlan M, Robles R, Solenthaler M, Laαmmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998;91:2839-2846 (Pubitemid 28227534)
8. Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002;100:778-785 (Pubitemid 34832601)
9. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994;83:2171-2179 (Pubitemid 24112728)
10. Kokame K, Matsumoto M, Soejima K, et al. Mutation and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002;99:11902-11907 (Pubitemid 34994496)
11. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043-4049
12. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584 (Pubitemid 28536132)
13. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398-403.
14. Galbusera M, Bresin E, Noris M, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005;106:925-928 (Pubitemid 41076435)
15. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 1995;122:569-572
16. Bell WR. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning. Semin Hematol 1997;34:134-139
17. Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica 2004;89:320-324 (Pubitemid 38788417)
18. Kwaan HC, Soff GA. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:159-166 (Pubitemid 27175074)
19. Pasquale D, Vidhya R, DaSilva K, Tsan MF, Lansing L, Chikkappa G. Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine. Am J Hematol 1998;57:57-61. (Pubitemid 28047200)
20. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002;206:519-527 (Pubitemid 36192911)
21. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004;124:787-795 (Pubitemid 38365784)
22. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002;28:385-391 (Pubitemid 35216402)
23. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003;138:105-108 (Pubitemid 36222497)
24. Barbot J, Costa E, Guerra M, et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001;113:649-651 (Pubitemid 32524384)
25. Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol 2000;65:251-255
26. Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004;77:171-176 (Pubitemid 39281865)
27. Darabi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006;125:592-597
28. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001;345:1000. (Pubitemid 34940822)
29. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000;96:1184-1186
30. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69 (Pubitemid 32064857)
31. Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006;28:211-214 (Pubitemid 43752222)
32. Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20:23-28 (Pubitemid 351339428)
33. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-470 (Pubitemid 23056436)
34. Baid S, Pascual M, Williams WW Jr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999;10:146-153 (Pubitemid 29034953)
35. Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006;69:436-439
36. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-3061 (Pubitemid 40057628)
37. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti- CD20. Blood 2003;101:3818-3826 (Pubitemid 36857852)
38. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67:283-287
39. Pekow J, Chung RT. Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab. J Clin Gastroenterol 2006;40:450. (Pubitemid 44318169)
40. Bestard O, Cruzado JM, Ercilla G, et al. Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant 2006;21:2320-2324 (Pubitemid 44295067)